CardiaMetrics is proud to be featured in Présences Grenoble, highlighting our journey and our ambition to transform heart failure care through innovative monitoring technologies.

Read the full article on Présences Grenoble.

A Growing Medtech Presence in Grenoble

The article highlights CardiaMetrics’ presence in the Grenoble ecosystem, a region recognized for its strong deeptech and healthcare innovation environment. Alongside our roots in Normandy, our footprint in Grenoble reinforces our ability to combine scientific excellence, engineering, and clinical partnerships.

This dual anchoring reflects our ambition to build a high-impact medtech company at the intersection of research, technology, and patient care.

Addressing a Major Unmet Medical Need

CardiaMetrics is developing a home-based remote monitoring solution for patients with heart failure, a chronic disease affecting millions worldwide.

As emphasized in the article, heart failure management remains a major challenge due to the difficulty of detecting early signs of decompensation. Our approach aims to provide continuous, reliable, and actionable physiological insights, enabling clinicians to intervene earlier and improve patient outcomes.

Innovation at the Core: Data, Sensors, and AI

The Présences Grenoble feature underlines the technological foundations of our solution, combining:

• Advanced physiological sensing
• Data science and machine learning
• A strong clinical validation strategy

By leveraging these pillars, CardiaMetrics is working to deliver scalable and clinically relevant monitoring, bridging the gap between traditional telemonitoring and more invasive solutions.

Building Momentum

This media recognition reflects the progress CardiaMetrics has made over the past months — from team growth and clinical development to increased visibility within the innovation ecosystem.

We are grateful for the continued support of our partners, investors, and the broader medtech community as we move forward.

CardiaMetrics is proud to announce that we have been selected to join the Deeptech Accelerator program led by Bpifrance, becoming the only startup from Normandy to be part of this prestigious cohort.

This recognition marks an important milestone in our journey to transform heart failure care through innovative remote monitoring technologies.

Read the full media coverage by Ouest-France

Recognition of Our Deeptech Vision

The Deeptech Accelerator supports high-impact startups developing breakthrough technologies grounded in strong scientific foundations. CardiaMetrics’ selection reflects the relevance of our approach combining advanced sensing technologies, machine learning, and clinical research to improve the management of heart failure patients.

Being part of this program will help us structure our growth, strengthen our industrial strategy, and accelerate clinical development, while benefiting from mentorship, funding support, and access to a powerful innovation ecosystem.

Strengthening Our Development Roadmap

Since our creation, CardiaMetrics has focused on building a clinically driven innovation, working closely with healthcare professionals and research partners to validate the safety and performance of our technology.

Participation in the Deeptech Accelerator will enable us to:

• Accelerate product development and regulatory readiness
• Expand clinical evidence generation
• Reinforce our strategic positioning in the heart failure monitoring market
• Scale our impact across France and internationally

A Collective Achievement

This milestone reflects the dedication of our growing team, the trust of our investors, and the support of our clinical partners.

We are honored to contribute to the dynamism of the Normandy deeptech ecosystem and to help position French innovation at the forefront of cardiovascular care.

Stay tuned for more updates as we continue to advance toward the next stages of clinical validation and market access.

We’re excited to share that CardiaMetrics was recently featured on RCF-Isère Radio’s Parole de leader programme, a series dedicated to showcasing leaders, entrepreneurs, and innovators shaping the economic and social landscape.

In this interview, Thibault Parmentier, CEO and co-founder of CardiaMetrics, spoke about our journey, our mission to improve the lives of patients living with chronic heart failure, and how our unique approach to telemonitoring can help clinicians anticipate cardiac decompensations before they become critical.

What We Discussed

• The inspiration behind CardiaMetrics and how we are building on years of research to develop an implantable telemonitoring solution.

• The clinical challenges of heart failure, and why early detection and continuous monitoring are essential for improving patient outcomes.

• How our technology works, with automated physiological data collection and predictive insights that empower clinicians to act proactively.

• The importance of collaboration with clinical partners and how evidence-based innovation is at the core of our strategy.

This radio feature is a meaningful opportunity to share our vision with a wider audience and highlight the real-world impact of innovation in cardiac care. We encourage all our community — patients, clinicians, partners, and supporters — to listen to the interview and gain insight into our mission.

Listen to the Parole de leader episode on RCF Radio (Economy & Society segment) to hear the full conversation with Thibault Parmentier.

Stay tuned to our blog for more media highlights and updates from the CardiaMetrics team!

We are thrilled to share that CardiaMetrics has been featured in La Gazette du Laboratoire! The article highlights our journey, our innovative implantable device for heart failure patients, and the team driving this technology forward.

Founded in 2023, CardiaMetrics builds on six years of R&D to develop a subcutaneous implantable system that monitors patients’ vital signs daily, anticipates cardiac decompensations, and improves quality of life at home. The Gazette Labo article details our transition from SentinHealth to CardiaMetrics, our shift from a gastric-based device to a subcutaneous approach inspired by implantable Holters, and the strong multidisciplinary team supporting this ambitious project.

The article also emphasizes our clinical ambitions, including ongoing trials at the CHU de Caen to validate both the safety and performance of the device. With a robust regulatory and quality framework, our system is designed to comply with international standards, ensuring reliable, clinically actionable insights for healthcare professionals.

We are proud to be recognized for our work in advancing remote monitoring for heart failure, a critical medical need affecting millions worldwide. This press coverage is a great opportunity for readers to learn more about our technology, team, and vision.

📖 Read the full article on La Gazette Labo here: CardiaMetrics, une startup spécialisée dans le développement d’un dispositif médical automatique implantable pour la télésurveillance de patients atteints d’insuffisance cardiaque.